Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biophan tightens grip on MRI (magnetic resonance imaging) safety sector:

This article was originally published in Clinica

Executive Summary

In what it claims gives it "market dominance in MRI safety", Biophan Technologies has been issued with a key US patent. The patent, explains the firm, is instrumental in securing the rights to its "anti-antenna" technology for making a broad range of medical apparatus - including pacemakers, surgical tools, and cardiovascular stents - safe for use with MRI systems. "Safety and image compatibility have long been major concerns when considering use of MRI ... with implanted devices," said Michael Weiner, the West Henrietta, New York firm's CEO. "We anticipate that this patent will protect the company's technology against the efforts of any other companies to make devices, such as pacemakers and neurostimulators, definitively safe for use with MRI machines."

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT060480

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel